A comprehensive view of Vertex Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Vertex to merge with biotechnology company ViaCyte for US$320M, with ViaCyte to become wholly-owned subsidiary of Vertex upon completion of deal; ViaCyte developing novel stem cell therapies as possible cure for type 1 diabetes
Published: July 13, 2022 by Marketline - Deals
FDA lifts clinical hold on Phase1/2 study of Vertex Pharma's stem cell-derived VX-880 injectable therapy to treat type 1 diabetes; trial reopening for screening, enrollment, dosing at sites in US
Published: July 06, 2022 by SeeNews Pharmaceuticals
Vertex reports Q1 GAAP net income up 17% from a year ago to US$762.0M, revenues up 22% year-over-year to US$2.1B, driven by Trikafta cystic fibrosis drug, with Health Canada approving drug for children 6-to-11 years of age; US sales up 9% year-over-year
Published: May 09, 2022 by Vertex Pharmaceuticals Inc.
FDA suspends early-stage clinic trial of Vertex’s VX-880 stem-cell therapy to potentially cure type 1 diabetes for ‘insufficient information’ to approve increased dose in tests; Vertex hopes continuing studies in Canada will assuage FDA concerns
Published: May 05, 2022 by The Boston Globe
Health Canada grants marketing authorization for Vertex’s oral Trikafta elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg and ivacaftor 75 mg to treat cystic fibrosis in kids 6-11 years old; CF affects about 500 kids in Canada, 83,000 people globally
Published: April 21, 2022 by Vertex Pharmaceuticals Inc.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count